Conventional treatment of high-grade glioma includes maximal surgical resection followed by external radiation therapy. Despite this treatment, the prognosis for patients is poor. High doses of chemotherapy might be another way to increase the response rate and median survival. Increasing doses of BCNU might be more effective, but also provokes unacceptable myelotoxicity. This doselimiting toxicity can be circumvented by using autologous blood stem cell rescue. We report our experience of highdose BCNU followed by transplantation of autologous hematopoietic stem cells in 114 patients with high-grade gliomas. Of the 114 gliomas, 78 were glioblastoma multiforme (GM) (68%), 24 anaplastic astrocytomas (AA) (21%), and 12 anaplastic oligodendrogliomas (OD) (11%). Complete surgical resection was performed for 22 patients (18 GM and 4 AA). The median age was 44 years (range 17-65). A total of 84 patients received autologous hematopoietic stem cells from bone marrow harvest, while 30 patients received granulocyte colony-stimulating factor followed by apheresis and received peripheral blood progenitor cells (PBPC). High dose of BCNU (800 mg/ m 2 ) was given at least 1 month after neurosurgery. Bone marrow or PBPC was transplanted 48-72 h after chemotherapy. Radiotherapy was started approximately 40 days after transplantation to a total of 60 Gy. Median follow-up was 89 months (19-163). The overall survival (OS) was, respectively, 12 months for GM, 37 months for OD and 81 months for AA. Histological type appeared to be the main discriminating factor, with a worse prognosis for GM. Within the GM population, age, completeness of surgery, and response appeared to be one important prognostic factors. The AA and OD populations were small to reliably assess prognostic factors. On multivariate analysis, the main prognostic factors were histologic type, quality of surgery, and age (Po0.005). Five of 114 patients had lethal complications from the procedure. Four of these patients had a Karnovsky performance score (KPS) of 60%. The protocol thus appears to be feasible but patients should be selected for KPS more than 70%. We observed long-term survivors, although the OS and the time to treatment failure seem to be comparable to that described for other treatment. Additional pilot studies are unlikely to reveal more than a modest benefit from this procedure and therefore a randomized study should be performed.
Summary:
Conventional treatment of high-grade glioma includes maximal surgical resection followed by external radiation therapy. Despite this treatment, the prognosis for patients is poor. High doses of chemotherapy might be another way to increase the response rate and median survival. Increasing doses of BCNU might be more effective, but also provokes unacceptable myelotoxicity. This doselimiting toxicity can be circumvented by using autologous blood stem cell rescue. We report our experience of highdose BCNU followed by transplantation of autologous hematopoietic stem cells in 114 patients with high-grade gliomas. Of the 114 gliomas, 78 were glioblastoma multiforme (GM) (68%), 24 anaplastic astrocytomas (AA) (21%), and 12 anaplastic oligodendrogliomas (OD) (11%). Complete surgical resection was performed for 22 patients (18 GM and 4 AA). The median age was 44 years (range 17-65). A total of 84 patients received autologous hematopoietic stem cells from bone marrow harvest, while 30 patients received granulocyte colony-stimulating factor followed by apheresis and received peripheral blood progenitor cells (PBPC). High dose of BCNU (800 mg/ m 2 ) was given at least 1 month after neurosurgery. Bone marrow or PBPC was transplanted 48-72 h after chemotherapy. Radiotherapy was started approximately 40 days after transplantation to a total of 60 Gy. Median follow-up was 89 months . The overall survival (OS) was, respectively, 12 months for GM, 37 months for OD and 81 months for AA. Histological type appeared to be the main discriminating factor, with a worse prognosis for GM. Within the GM population, age, completeness of surgery, and response appeared to be one important prognostic factors. The AA and OD populations were small to reliably assess prognostic factors. On multivariate analysis, the main prognostic factors were histologic type, quality of surgery, and age (Po0.005). Five of 114 patients had lethal complications from the procedure. Four of these patients had a Karnovsky performance score (KPS) of 60%. The protocol thus appears to be feasible but patients should be selected for KPS more than 70%. We observed long-term survivors, although the OS and the time to treatment failure seem to be comparable to that described for other treatment. Additional pilot studies are unlikely to reveal more than a modest benefit from this procedure and therefore a randomized study should be performed. Bone Marrow Transplantation (2003) 31, 559-564. doi:10.1038/sj.bmt.1703889 Keywords: malignant glioma; high-dose BCNU; autologous transplantation Therapeutic management of high-grade gliomas remains difficult. Conventional treatments include maximal neurosurgical resection followed by external radiation therapy. Despite these treatments and their improvements, the prognosis for newly diagnosed patients is poor. The majority of them will die, high-grade glioma being one of the most common causes of cancer-related death in young adults. The median survival is a little more than 1 year, with exceptional survivors after 5 years. [1] [2] [3] [4] [5] While several chemotherapeutic agents have been shown to be effective in vitro, many of them do not seem to be very active in vivo. Nitrosoureas such as BCNU and CCNU, dacarbazin, cisplatin, carboplatin, thiotepa, temozolomide, procarbazine, vincristine, and paclitaxel have been tested as single agents in phase I or II study, with generally disappointing results. [6] [7] Polychemotherapy did not give better results except for the combination of lomustine (CCNU), vincristine, and procarbazine (PCV) when compared to BCNU alone. [8] [9] According to Fine et al 1 and Stewart et al 10 using adjuvant chemotherapy might be more effective, giving overall survival (OS) and progression-free survival benefits. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] However, despite the improvements in chemotherapy, the development of newer agents or the use of new delivery systems, the therapeutic benefit remains low.
The lack of responsiveness to chemotherapy can be explained by the presence of the blood-brain barrier, the abnormal vascular supply associated with high-grade gliomas, cellular heterogeneity of the tumor, and/or intrinsic or acquired drug resistance frequently seen with these tumors. Agents such as nitrosoureas have been developed to circumvent these barriers. These are rationally designed drugs that are highly lipid-soluble, of low molecular weight, and not ionized. They may, therefore, more easily cross the blood-brain barrier and penetrate well into the brain, providing effective treatment against high-grade gliomas.
High-dose chemotherapy is based on the observation of a marked dose-response relation for many cytotoxic agents. This has been proven, for example, in hematologic malignancies, but not yet in treatment of gliomas. However, using high-dose chemotherapy for this indication might be another way to increase the level of drugs penetrating the blood-brain barrier. Furthermore, tumor cytotoxic resistance may be overcome by marked dose escalation. The agents to be used at high doses should be capable of adequate penetration of the CNS, have some degree of effectiveness at standard doses, and be sufficiently tolerable for sick patients. The nitrosourea BCNU might meet these criteria. Conventional BCNU for high-grade gliomas used doses of 150-300 mg/m 2 , delivered intravenously every 6-8 weeks. 11 If used in higher doses, BCNU might be more effective but also provokes unacceptable myelotoxicity. This dose-limiting toxicity can be circumvented by using autologous marrow or peripheral blood stem cell rescue. Unlike with other malignancies, in patients with gliomas, the graft is usually not contaminated by malignant cells. This procedure has been tried by several groups, with inconclusive results. [12] [13] [14] [15] [16] [17] [18] [19] [20] We report our experience of high-dose BCNU in 114 patients with high-grade gliomas treated from October 1988 to December 1998. The high-dose chemotherapy was followed by transplantation of autologous hematopoietic stem cells from marrow or peripheral blood.
Patients and methods

Patients
Between October 1988 and December 1998, 114 selected and newly diagnosed patients with high-grade gliomas were treated with high-dose BCNU (84 males and 30 females) in a pilot study. Patients eligible for this treatment were required to have undergone primary neurosurgical biopsy or surgery to prove a high-grade glioma and have a Karnovsky performance score (KPS) of at least 60%. Exclusion criterea included insufficient organ function (serum creatinine 41.5 mg/dl or liver failure), 465 years of age, or insufficient stem cell progenitor collection (o2 Â 10 6 CD34+ cells/kg). According to Fleming 21 the major stopping criterion was more than two deaths for each 30 patients included.
Median age was 44 years (range 17-65). Depending on histology, the age differed significantly, with a median age of 47.5 years for glioblastoma multiforme (GM), of 39 for anaplastic astrocytomas (AA) and of 38 for oligodendrogliomas (OD) (P ¼ 0.00012).
A total of 78 patients had GM (68%), 24 had AA (21%), and 12 had anaplastic OD (11%). Complete surgical resection was performed for 22 patients (18 GM and 4 AA). Table 1 summarizes the main characteristics of the surgery.
Patients received no prior chemotherapy or radiotherapy and had adequate renal and liver function and bone marrow reserve.
KPS was at least 60% with a median of 90 (range 60-100%).
Autologous hematopoietic stem cell collections
Autologous hematopoietic stem cells were obtained for 84 patients by bone marrow harvest (BMH) under general anesthesia on the day of high-dose chemotherapy. The buffy coat was stored at 41C in 4% albumin. For the 30 other patients, 5 mg/kg granulocyte colony-stimulating factor (G-CSF) was administered subcutaneously twice daily for 4 days to mobilize peripheral blood progenitor cells (PBPC). Collections by apheresis began on day 5 and were repeated daily until a minimum of 2 Â 10 6 CD34+ cells/kg were obtained. Cryopreservation was performed according to the standard procedures.
Treatment modalities and supportive care
High-dose chemotherapy was scheduled at least 1 month after neurosurgery. All patients were given 100 ml of 20% mannitol and then received a single dose of BCNU (carmustine, 800 mg/m 2 ) intravenously given over 90-120 min according to immediate tolerance. Patients received 2-3 l of hydration, started 12 h before chemotherapy and stopped 24 h after transplantation. Methylprednisolone and 20% mannitol were infused according to tolerance. Bone marrow or PBPC was transplanted 48-72 h after chemotherapy.
Patients were discharged from hospital and followed weekly on an outpatient basis. Hematopoietic recovery was evaluated by complete CBC performed twice a week for 6 weeks. Blood products were administrated if the hemoglobin level was o8 g/dl and the platelet count o50 Â 10 9 /l. Medical history, physical examination including detailed neurological examination, and liver tests were required once a week for 4 weeks. Toxicities were evaluated according to the OMS common toxicity criteria. Chest X-rays were performed when indicated by clinical examination.
Radiotherapy for all patients was started approximately 40 days after transplantation. Adjuvant irradiation was High-dose BCNU in high-grade glioma X Durando et al carried out using a linear accelerator. Around 60 Gray (Gy) or a biologically equivalent dose was delivered according to conventional fractionation (2 Gy/day) or hypofractionation (3 Gy/day) with split-course (30 Gy+15 Gy), respectively.
Evaluation of tumor response and survival
All successive clinical or radiological evaluations were done with patients receiving a stable steroid dose. Brain CT-scan or MRI was usually performed at diagnosis, after surgery, 1 month after high dose of BCNU (before radiotherapy) and then at 3-month intervals for 1 year and every 6-12 months thereafter.
Macroscopic complete surgery was defined by a CT-scan or MRI performed after surgery, in which no identifiable tumor or heterogeneous contrast enhancement could be seen. Details of the type of surgery according to histology are presented in Table 1 .
For patients who underwent biopsy or partial surgery, responses were defined as follows. A complete response (CR) was defined if all the measurable tumor disappeared for more than 1 month. A partial response (PR) was defined as a 450% reduction in the sum of the products of the two greatest perpendicular diameters of each measurable lesion. Stable disease (SD) was defined as a o25% increase or a o50% reduction in that sum, and progression of disease (PD) as a 425% increase in that sum or the appearance of new lesions.
The primary end point in this analysis was OS. We also defined and evaluated the time to treatment failure (TTF) as the time between treatment and relapse for patients with complete surgery and as the time between treatment and disease progression for patients with partial surgery. Disease activity was evaluated as no evidence of clinical disease, suspicion of relapse, and clear clinical progression. However, progression was definitely confirmed by CT-scan or MRI. Definite evidence of tumor growth defined the TTF.
KPS was used to assess quality of life of individual patients during treatment.
Statistical analysis
Survival curves were generated using the Kaplan-Meier method. 22 Medians for survival and TTF are estimates based on this method. The Cox proportional hazards model was used to analyze the effect of covariates on survival and time to failure or progression. Standard tests were used for distribution parameters and links analysis. Data analysis was performed with SEM software. 23 All analyses are based on evaluable patients as defined above.
Survival was calculated after engraftment rather than at the time of surgery, since seven patients had their transplant more than 1 year after their diagnosis.
Results
Engraftment, transplantation-related adverse effects, and toxicities
Autologous hematopoietic stem cells were obtained by BMH for 84 patients and by apheresis after stem cell factor administration for 30 patients. All patients achieved complete hematopoietic recovery by day 45. In all, 60 patients received at least one platelet transfusion and 18 received blood transfusions. Platelet transfusions were more frequent in patients undergoing BMH (61% for BMH vs 30% for PBPC (P ¼ 0.004)). No blood transfusions were performed for the 30 patients who underwent PBPC transplantation. Two patients were hospitalized for infectious complications, which were successfully treated.
Toxicities are presented in Table 2 . Seven patients died during the therapeutic protocol. Two underwent transtentorial herniation with brain distortion suggesting evolution of their disease. Of the five others, one died of lung fibrosis and four of unknown causes but probably to treatment-related complications. Before treatment these four patients had a KPS of 60%, the limit of inclusion for this study.
Survival analysis
At the time of analysis, 27 of the 114 patients were alive, with 11 who were undergoing relapse or progression. Median follow-up was 89 months (range from 19 to 163). OS for each histology is presented in Figure 1 . The median OS were, respectively, 12 months for GM, 37 months for OD and 81 months for AA.
Prognostic factors
Prognostic factors were only studied in relation to OS, this factor being more objective. The main prognostic factors ) and histology. The poorer survival of GM (median ¼ 12 months) compared with AA (81 months) and OD (37 months) was highly significant (P ¼ 4.4 Â 10 -6 ) ( Figure 1 ). Sex, initial KPS (100+90 vs p80) and initial tumor size did not constitute prognostic factors.
Since histology appeared to be the main discriminating factor, prognostic factors were evaluated for each type of high-grade glioma. Owing to the small population, no evident prognostic factors were found for AA and OD. In the GM population, age appeared to be an important prognosis factor (p50 vs 450: Po0.001). Type of surgery also clearly influenced OS (Figure 2 ). Complete surgery included of good prognosis, when achieved. The median OS was 11 months after partial surgery and 20 months after complete surgery. In both other histologies, significance was not obtained because of sample size.
Using the Cox model, the main prognostic factors were successively histologic type, resection type, and age (Po0.005).
Antitumor effect for patients without complete resection and evaluable tumor
Of the 114 patients treated, 71 had measurable tumor (44 for GB, 19 for AA, and 8 for OD), 22 underwent a complete resection and 21 were unevaluable (CT-scan or MRI not performed or tumor unmeasurable). Table 3 presents the quality of the tumor response for the 71 patients according to histology. The 71 patients were evaluated a mean of 71 days after radiotherapy (range 15-120 days). All the patients who underwent CT-scan or MRI within 60 days after radiotherapy developed exacerbations of neurologic problems which were confirmed as owing to tumor evolution.
Survival of these patients was studied to measure the influence of chemotherapy and radiotherapy according to histology. AA and OD subtypes cannot be analyzed because of the small sample size. For the 44 evaluated GM patients, OS according to tumor response is presented in Figure 3 . In comparison to the progressive patients, complete or partial responses gave significantly better OS (P ¼ 0.02). 
Table 3
Tumor response for patients without complete resection and evaluable tumor GM (44) AA (19) OD (8) High-dose BCNU in high-grade glioma X Durando et al
Discussion
In order to achieve long-term survival for high-grade gliomas, more aggressive treatments or invasive techniques are being developed. High-dose chemotherapy may be delivered by either intratumor implantable systems, intraarterial chemotherapy or high doses of intravenous drugs. For regional treatment with local delivery systems, various chemotherapeutic agents have been tried, such as BCNU, cisplatin, and bleomycin/mitomycin-C. 24 The results remain inconclusive mainly because more patients need to be studied. Drug diffusion to the outer margin of the tumor, maintenance of sufficiently high intratumoral drug levels, biodegradation of the drugs, and their bioavailability are all factors, which might reduce the efficiency of these local treatments. Intra-arterial chemotherapy has been tested because of the theoretical advantage of increased regional drug delivery with decreased systemic intravenous toxicity. In some reports, high complication rates have been observed, and in others median survival was not significantly improved. 25, 26 This therapeutic procedure is now infrequently used.
Intravenous chemotherapy, especially with nitrosoureas, is known to have some therapeutic effects. 1, 10 However, systemic drug diffusion can induce severe toxicity. Bone marrow toxicity is the dose-limiting factor for nitrosoureas, and therefore high-dose BCNU has been tested with autologous stem cell rescue since the 1980s. The first studies were performed on recurrent tumors or incomplete resections. [12] [13] [14] [15] [16] [17] [18] None of these authors used exactly the same dose of BCNU (from 800 to 1400 mg/m 2 ). The observed toxicities were very variable, as were the delivery procedures. The combined data suggested that tumor response rate was improved over that expected of conventional treatment, although the median survival did not appear to differ significantly. However, some long-term survivors were reported, suggesting that a small number of these recurrent, refractory, or unresectable tumors might benefit from this treatment. A few larger trials ensued these first reports. Phillips et al 16 treated 36 patients (nine with adjuvant and 27 with recurrent disease) with high dose BCNU. In the first group of patients he observed three with long disease-free survivals. In the second group, 12 patients experimented durable responses with long disease-free survivals for two of them. Biron et al 19 reported 89 newly diagnosed high-grade gliomas and nine with relapse in 1991. Patients received 800 mg/m 2 of BCNU and then radiation therapy. They found a toxic mortality of 6.1%. The OS was 10% at 36 months and the median survival time after BMT of 11 months. Linassier et al 20 reported 39 patients who received 800 mg/m 2 of BCNU followed by BMT and then radiation therapy. Complete surgical resection was performed for 21 patients, while 17 underwent partial resection and one a biopsy. They found a median survival time of 14 months with a probability of survival of 37% at 2 years and 25% at 5 years. With a median follow-up of 28 months, relapse-free survival and OS were 16 and 25%, respectively.
High-dose BCNU can be administered, but toxicities should be mentioned even if we did not observe any serious immediate intolerance. Two patients underwent transtentorial herniation with brain distortion, suggesting that this treatment should not be performed in patients with unstable disease, particularly in the presence of high brain pressure. Interstitial pneumonia was reported for six patients with one lethal outcome. Four patients with a KPS of 60% died during the procedure. This should mandate a better choice of patients for this procedure (KPS more than 70%). As reported in the literature, transfusions after BMT appear to be more frequent than after PBPC, suggesting that the latter procedure is safer. 27 On multivariate analysis, three major prognostic factors can be assessed from our results. The first is histologic type of the tumor, with OS of GM being very low and OD and AA survival being longer. Our results also show that quality of the surgery and age are major prognostic factors, in agreement with Linassier et al 20 and Lacroix et al. 28 The OS of GM with complete resection was 20 months rather than 11 months after partial surgery. This result should urge surgeons to perform the most complete surgery possible. Furthermore, we observed four long-term survivors (two with complete resections and two with partial resections). These observations suggest that using high-dose BCNU for GM after complete resection might be of clinical interest. However, long-term survivors have also been reported with other treatments. An histologic review of these patients might be of interest. Of the 44 GM without complete resections, we observed 10 patients in CR or PR. Their OS was the same as for those who were stable after treatment. Among these patients, we observed two longterm survivors, suggesting that some patients may benefit from this treatment even if they did not undergo complete resections. This observation has been also reported by Biron et al 19 and Linassier et al. 20 We conclude that high-dose BCNU appears to be feasible although we should endeavor to reduce lethal toxicity. Patients with a KPS of o70% should be excluded from this procedure. High-dose BCNU might be of interest in patients who have undergone complete surgical resection; however, histological type of the tumor remains the highest prognostic factor. Although the median survival time is not significantly different, this treatment strategy might result in long-term survivors. Additional pilot studies are unlikely to better define any benefit of this procedure. A randomized trial comparing high-dose BCNU to conventional BCNU treatment is under way and will assess cost-benefit and better evaluate the value of this procedure.
